The roles of recombination and accumulation of point mutations in the origin of new poliovirus (PV) characteristics have been hypothesized, but it is not known which are essential to evolution. We studied phenotypic differences between recombinant PV strains isolated from successive stool specimens of an oral PV vaccine recipient. The studied strains included three PV2/PV1 recombinants with increasing numbers of mutations in the VP1 gene, two of the three with an amino acid change IAT in the DE-loop of VP1, their putative PV1 parent and strains Sabin 1 and 2. Growth of these viruses was examined in three cell lines: colorectal adenocarcinoma, neuroblastoma and HeLa. The main observation was a higher growth rate between 4 and 6 h post-infection of the two recombinants with the IAT substitution. All recombinants grew at a higher rate than parental strains in the exponential phase of the replication cycle. In a temperature sensitivity test, the IATsubstituted recombinants replicated equally well at an elevated temperature. Complete genome sequencing of the three recombinants revealed 12 (3), 19 (3) and 27 (3) nucleotide (amino acid) differences from Sabin. Mutations were located in regions defining attenuation, temperature sensitivity, antigenicity and the cis-acting replicating element. The recombination site was in the 59 end of 3D. In a competition assay, the most mutated recombinant beat parental Sabin in all three cell lines, strongly suggesting that this virus has an advantage. Two independent intertypic recombinants, PV3/PV1 and PV3/PV2, also showed similar growth advantages, but they also contained several point mutations. Thus, our data defend the hypothesis that accumulation of certain advantageous mutations plays a key role in gaining increased fitness.
INTRODUCTION
Human enteroviruses (HEVs) cause a variety of clinical diseases, e.g. acute flaccid paralysis, encephalitis, acute haemorrhagic conjunctivitis, diabetes, myocarditis and skin disorders, but mostly they circulate subclinically. The genus Enterovirus (belonging to family Picornaviridae) comprises more than 200 different human serotypes. They are presently divided into the species HEV-A, HEV-B, HEV-C plus polioviruses (PVs), HEV-D, human rhinoviruses (HRV)-A and HRV-B according to their molecular and evolutionary properties (http://www.ictvonline.org/ virusTaxonomy.asp?version=2008&bhcp=1). Polioviruses (PVs), which were previously classified as a separate group, are genetically closely related to HEV-C and are currently reclassified into this species (Stanway & Knowles, 2008) .
The enterovirus genome is a 7500 nt single-stranded RNA molecule with a messenger-sense polarity. RNA viruses are known to have a highly variable genome manifested by point mutations due to the lack of a proof-reading mechanism of the RNA-dependent RNA polymerase. As a consequence, mutations accumulate in their genomes and variants with advantageous properties become selected and enriched. Part of the genomic heterogeneity of RNA viruses is caused by genetic rearrangements, i.e. recombination or gene transfer. Homologous recombination of RNA viruses is considered to mainly occur during synthesis of negative strands, known as strand-switching, which leads to replicative recombination (reviewed by Agol, 1997) . A non-replicative RNA recombination model, where recombining RNAs are cleaved and exposed termini are crossligated, has also been proposed (Gmyl et al., 1999) . Recombination of PVs was discovered in vitro in the 1960s (Hirst, 1962; Ledinko, 1963) . Recently, natural PVs have been shown frequently to participate in recombination events. In vaccinees immunized with live oral PV vaccine (OPV), comprising serotypes 1, 2 and 3 of PV, intertypic recombinants can be reproducibly isolated (Cammack et al., 1988; Minor et al., 1986b) . Serotypes 1, 2 and 3 of wild-type PVs have been reported to recombine with each other (Dahourou et al., 2002; Furione et al., 1993) . Wild-type and OPV strains have been reported to recombine (Dahourou et al., 2002; Georgescu et al., 1995; Guillot et al., 2000; Liu et al., 2000 Liu et al., , 2003 Yang et al., 2003) and PVs have been shown to recombine with serotypes of HEV-C (Brown et al., 2003; Jiang et al., 2007; Rousset et al., 2003) . Furthermore, vaccine-derived PV strains, defined as having more than 1 % nucleotide differences in the VP1 protein coding region (reviewed recently by Agol, 2006; Kew et al., 2004) , have been reported to have an interserotypic recombinant genome (Blomqvist et al., , 2004 Martin et al., 2002) as well as a recombinant genome with a non-structural region from an unknown HEV-C strain (Arita et al., 2005; Kew et al., 2002 Kew et al., , 2004 Rakoto-Andrianarivelo et al., 2008; Rousset et al., 2003; Shimizu et al., 2004) . The enterovirus recombination sites are located in the 59 non-coding region (NCR) and in the non-structural part of the 7500 nt genome in genes coding for proteins 2A, 2B, 2C and 3D. In addition, recombination in the capsid protein VP1 coding region has been shown Dedepsidis et al., 2008; Liu et al., 2000; Martin et al., 2002) , as well as recombination in the VP2 protein coding gene (Kyriakopoulou et al., 2006) . In addition to within-species recombination events, interspecies recombination has been suggested for HEV-B and HEV-C strains (Bolanaki et al., 2007) . The interspecies recombinants between PVs and other HEV species (excluding HEV-C) have not been reported in vivo, but several kinds of experimental crosses have been shown to be viable (Johnson & Semler, 1988; Lu & Wimmer, 1996; Rieder et al., 2003) .
Recombination is thus a recurrent phenomenon in the PV life cycle and it seems that the partner for gene transfer can be any virus with a sufficiently similar genome. As recombination is likely to occur more frequently than is manifested in the predominant progeny, it is interesting to question what defines the viability and fitness of the recombinant strain. It is postulated that recombination occurs to increase or restore the genetic fitness of a PV vaccine strain (Agol, 2006; Lai, 1992) . At the same time, it has long been known that point mutations accumulate in the genome of OPV-derived PVs during replication in the human gut. It is obvious that these also result in phenotypic features that improve the fitness. We had access to successive stool specimens from OPV recipients and decided to search for, and phenotypically characterize, closely related strains isolated around a potentially recently emerged recombinant. We aimed to compare the phenotypic characteristics of these strains and elucidate the roles of different genetic changes behind them.
METHODS
Virus samples and propagation in cell culture. PV-containing faecal samples were collected from healthy children in an orphanage in Minsk, Byelorussia, after vaccination with trivalent OPV. The material has been described previously (Samoilovich et al., 2003) . The PV strains used in this study are shown in Table 1 . Freezer stocks of the isolated strains were plaque-purified at 36 uC in green monkey kidney (GMK) cells according to a method previously described by Mulders et al. (1999) or in the presence of polyclonal antisera obtained from the National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Plaques were collected and passaged once in GMK cells [1 : 3 dilution in cell culture medium (MEM) with 1 % FBS] at 36 uC to full cytopathic effect (CPE). Cultures were freeze-thawed three times and clarified by centrifugation for 10 min at 235 g. The supernatant was collected and stored at 270 uC. The plaque isolates (Table 1) with sequenceconfirmed recombinant nature were grown to full CPE in GMK cells at 36 uC in 250 ml flasks. The serotype of the stock isolate was confirmed by plaque neutralization at 36 uC with type-specific polyclonal antisera obtained from RIVM.
Isolation of RNA and RT-PCR. Viral RNA was isolated from 100 ml tissue culture supernatant using E.Z.N.A. Total RNA kit (Omega BioTek). Upon purification, RNA was eluted from the columns with 30 ml diethyl pyrocarbonate-treated H 2 O and subsequently stored at 220 uC. RT-PCR was performed using the conditions described by Oberste et al. (1999) with primers Y7 and Q8 (El Bassioni et al., 2003) for VP3/2A, and 257994 and 257995 (Pulli et al., 1995) for partial 3D. In addition, primers PV1A and PV2S (El Bassioni et al., 2003) were used for sequencing of VP1; otherwise sequencing was performed with the same primers as RT-PCR. For complete genome sequences, several primers were used following the primer walking strategy. PCR products were purified with the QiaQuick gel extraction kit (Qiagen).
Sequencing and sequence analysis. Sequences were generated by the Molecular Medicine Sequencing Laboratory, Biomedicum, Helsinki, Finland, with full service sequencing including sequencing reactions with a BigDye Terminator cycle sequencing ready reaction kit v3.1 (Applied Biosystems), dilution 1/18, and a sequencing run *AP denotes anti-polio, the original sample mixture was treated with antisera against either serotype.
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with the ABI3730 Automatic DNA Sequencer (Applied Biosystems). Sequence data were analysed using Vector NTI Suite 10 (Invitrogen), assembled using ContigExpress and aligned using AlignX software. Multiple sequence alignments were made with AlignX as well as CLUSTAL_X 1.83 (Thompson et al., 1997) using default parameters. Similarity analysis was performed with SimPlot software package version 2.5 (Lole et al., 1999) . A sliding window of 200 nt moving in steps of 20 nt was used.
Growth kinetics in different cell lines. Human colorectal adenocarcinoma (CaCO-2; ATCC), human neuroblastoma (SK-N-SH; kindly provided by Antti Vaheri, University of Helsinki, Finland) and the Ohio strain of HeLa (kindly provided by Eurico Arruda, University of Virginia, Charlottesville, USA) cells were infected with equal amounts of each virus (m.o.i. of 4). One cycle growth curves were determined at 36 uC by collecting samples at different times post-infection (p.i.). The viral titres of the samples were subsequently assayed in duplicate using the end-point dilution method. The growth curves of all PV2/PV1 recombinant strains, PV2-31996, PV2-32189+AP1 and PV2-32191, their parental strains in all cell lines and PV3/PV1 and PV3-33239 were determined. The growth curve for the PV3/PV2 recombinant, PV3-31974, was determined in SK-N-SH cells.
Temperature sensitivity assay. Viral growth at 36 and 39 or 40 uC was assayed by the plaque titration method as well as the TCID 50 method in GMK cells. A temperature sensitivity test was performed on PV2/PV1 recombinants PV2-31996, PV2-32189+AP1 and PV2-32191 as well as their parental strains. 
RESULTS

Genetic features
We studied a set of PV2/PV1 recombinant strains, first identified as such based on the VP1 and partial 3D sequences, isolated from a healthy child 1-5 weeks after the first dose of OPV. The recombinants, PV2-31996, PV2-32189+AP1 and PV2-32191, were a series of strains with an increasing amount of nucleotide substitutions in VP1. The latter two of these isolates also had one amino acid change of IAT at position 143 in the DE-loop of VP1. This amino acid is known to attenuate PV2 (Kew et al., 2004; Ren et al., 1991) , and in these isolates, it had reverted back to wild-type. A similar reversion to wild-type (as the sole amino acid mutation in VP1) has been connected previously to vaccine-associated paralytic poliomyelitis (Cherkasova et al., 2005) . A potential PV1 parent of these recombinants, PV1-32189+AP2, was also found and identified as having the same 3D mutation profile as PV2-31996 without recombination. In addition to the PV2/PV1 recombinants, we studied a PV3/PV1 recombinant PV3-33239 and a PV3/PV2 recombinant PV3-31974.
The (almost) complete genomic sequences of the studied strains were determined in the following regions: PV2-32191, nt 1-7440; PV2-32189+AP1, nt 13-7440; PV2-31996, nt 1-7434; PV3-31974, nt 106-7432; PV3-33239, 1-7432. The sequences of all recombinants were compared to parental Sabin strains. The nucleotide and amino acid differences are presented in Table 2 . The PV2/PV1 strains PV2-31996, PV2-32189+AP1 and PV2-32191 had a total of 12 (3), 19 (3) and 27 (3) nucleotide (amino acid) differences compared with Sabin, respectively. The nucleotide identities were 99.84, 99.74 and 99.60 %, respectively. In addition to the above-mentioned amino acid substitution in VP1, two other amino acid substitutions were observed in all strains. PV2-32191 had two substitutions in the capsid coding region. The first was in VP3, at the recognized neutralizing antigenic site 3B (Minor et al., 1986a) , and the second in VP1-143, in the known attenuation site exposed in the DE-loop (Hogle et al., 1985) . The amino acid substitution in PV2-32189+AP1, in addition to the VP1-143 substitution, resided in the nonstructural protein coding region in 2A, with no known specific biological function. The amino acid substitutions of PV2-31996 were solely in the non-structural protein coding region in 2C and 3A and were not connected to known biological functions. The nucleotide mutations in all strains were located along the genome (Table 2 ). Each strain also had a nucleotide mutation in 2C, coding for the loop of the cis-acting replication element (CRE). The site of recombination in each strain was pinpointed to the beginning of the 3D polymerase coding region, at nt 6197-6231 in the PV2-Sabin genome (Fig. 1a) . Each strain had one shared amino acid substitution in the PV1 tail residing in the 'palm' of the 3D polymerase in motif A (Kok & McMinn, 2009; Thompson & Peersen, 2004) .
The nucleotide identity of the PV3/PV1 recombinant, PV3-33239, was 99.44 % compared with Sabin. There was a total of 41 nucleotide mutations, with eight of them leading to amino acid changes ( Table 2 ). The recombination site was located near the junction of 2C and 3A, at nt 5015-5021 in the PV1 genome (Fig. 1b) . The PV3/PV2 recombinant, PV3-31974, had a nucleotide identity of 99.62 % compared with Sabin. There was a total of 28 and 7 nucleotide and amino acid changes, respectively ( Table 2 ). The recombination site was in the 2B protein at nt 3920-3933 in the PV3 genome (Fig. 1c) . Nucleotide 472, which defines attenuation in the 59 NCR, had reverted back to wild-type in both PV3 recombinants, as is often seen in PV3 OPVderived strains (Rakoto-Andrianarivelo et al., 2008; Shahmahmoodi et al., 2008) . However, the sites defining attenuation in VP3 (2034) and VP1 (2493) were unchanged, as also seen in other described PV3 OPVderived strains (Shahmahmoodi et al., 2008) . There were no changes in the antigenic sites or the CRE region of 557TAG  668GAA  VP4  759AAG  759AAG  759AAG  820CAT  961GAA  865GAA  VP2  1233TAC  1233TAC  1233TAC  1040TAA 100SAT  1117AAG  1371CAT  1120TAC  1222GAA  1258AAG  1463GAA 241EAK  1645CAT  VP3  1990AG  415TAAD  1861TAC  1873AAG  2250GAA  2084AAG 448TAA  1991GAA  2409GAA  2409GAA  2410CAT  2150AAG 470IAV  2413TAC  2431AAG  2419TAA 559DAE  VP1  2526AAG  2834TAC  2637CAT 632AAV  2909TAC 721IATd 2909TAC  721IATd  3367GAA  2790TAC 683MAT  2932TAC  3084TAA  3084TAA  3084TAA  3330TAA  3378GAA  2A  3455AAT  903QAL  3460AAG  3364TAC  3658AAG  3409TAA  3682CAT  3511AAT 923KAN  3552CAT 937AAV  2B  4029CAT  3945AAG  4071GAA  2C  4308CAA  4129GAA 1395DAN 4188GAA  4473GAA §  4473GAA §  4473GAA §  4925GAA  4299TAC  4779AAG  4779AAG  4443TAC  4893CAT  4800TAC  5011TAA 1422SAT  5091CAT  3A  5341GAA  5119CAT  5342TAC 1532VAT  3B  5343CAT 1600IAV  3C  5514GAA  5449CAT  5545AAG  5562AAG  5536CAT  5845CAT  5595GAA  5800AAG  5884TAC  5925TAC  5833TAC  5932CAT  5972CAA 1745TAN  3D  6183GAA  6183GAA  6183GAA  6205CAT  6078TAC either of the PV3 strains. In contrast, there were several other nucleotide changes in both PV3 recombinants; however, these were not in the same sites as in other reported PV3 OPV-derived strains (Martin et al., 2000) .
Phenotypic characteristics
One step growth curves for PV2/PV1 recombinants and reference strains were determined in three cell lines, CaCO, SK-N-SH and HeLa (Fig. 2) . This indicated that PV2-32191 and PV2-32189+AP1 had faster growth rates between 4 and 6 h p.i. This was especially clear in CaCO cells, where the slope of the PV2-32191 and PV2-32189+AP1 growth curves is essentially steeper than that of the Sabin strains. All PV2/PV1 recombinants had faster growth rates than the parental Sabin 2 during the exponential phase of the replication cycle in CaCO cells. Both studied Sabin strains also had the lowest end titres at 48 h p.i., although the differences were small and within normal assay variation limits (data not shown). In SK-N-SH cells, PV2-32191 and PV2-32189+AP1 again grew most efficiently between 4 and 6 h p.i. Parental Sabin 2 still had the lowest end titre. In contrast, in HeLa cells, the superior growth rate of PV2-32191 and PV2-32189+AP1 was less clear. Both strains replicated somewhat faster between 2 and 5 h p.i., and Sabin 2 remained the least efficient strain at this stage. Interestingly, the putative PV1 parent of the recombinants, PV1-32189+AP2, showed a much lower rate of replication in both CaCO and SK-N-SH cells than the corresponding vaccine strain Sabin 1.
The growth properties of two independent recombinants, PV3-33239 (PV3/PV1) (Fig. 3) and PV3-31974 (PV3/PV2) (Fig. 4) , were found to be remarkably similar to those of the above PV2/PV1 recombinants. The PV3/PV1 and PV3/ PV2 recombinants had a faster growth rate than the parental Sabin 3 in SK-N-SH between 2 and 6 h p.i. PV3-33239 replicated with the same efficiency as PV1-Sabin in all studied cell lines (Fig. 3) . PV3-31974 reached exponential growth phase almost 2 h before Sabin 2 (Fig. 4) .
A noticeable difference was observed in the temperature sensitivity of the PV2/PV1 recombinants PV2-32191 and PV2-32189+AP1 compared with all of the other studied type 2 PV strains (Table 3) . These strains had apparently lost their temperature sensitivity and they replicated equally well at elevated temperatures. The plaque sizes at both temperatures were also essentially larger for PV2-32191 and PV2-32189+AP1 compared with Sabin (data not shown). The third recombinant, PV2-31996, with intermediate plaque sizes (data not shown), and the putative parental PV1, PV1-32189+AP2, had Sabin-like reproductive capacities at the different temperatures.
In a competition assay of five consecutive passages, the most mutated PV2/PV1 recombinant, PV2-32191, beat parental Sabin 2 in all three cell lines and was sequenced as a predominant type. In a competition between PV2-32191 and Sabin 1, a mixture of viruses was still seen in SK-N-SH and HeLa cells, while in CaCO cells, the recombinant was the prevailing type. When Sabin 1 and Sabin 2 competed with each other, Sabin 1 only was sequenced in the fifth passage in SK-N-SH and HeLa cells, while in CaCO, a mixture was still present. When PV2-32191 was passaged five consecutive times in three different cell lines, no mutations were observed in the VP1 sequence. 
DISCUSSION
In this study, we have investigated the phenotypic and genetic characteristics of natural recombinant strains of OPV-derived PVs in order to understand the biological benefits caused by recombination and accumulation of point mutations. We have compared the phenotypic and genetic features of a set of three PV2/PV1 recombinant strains isolated from successive stool specimens of an infant after receipt of the first dose of OPV. On top of the recombination, all PV2/PV1 recombinants had an increasing number of point mutations, including a non-silent one resulting in an amino acid substitution in the VP1 protein.
Moreover, we studied the growth properties of independent PV3/PV1 and PV3/PV2 recombinant strains that also had a number of point mutations. Thus, definite conclusions on the effect of only recombination on virus replication cannot be drawn from these data. However, based on the comparison of growth properties of several recombinant PV strains, we are able to present phenotypic differences contributing to increased fitness.
The genomes of the three PV2/PV1 recombinant strains share several nucleotide substitutions, and apparently the recombination site, suggesting a common OPV-derived ancestor. However, each of the strains also has distinct strain-specific substitutions, indicating that the strains are not necessarily successive members of a single diversification lineage. It is possible that a descendant of Sabin 2 first accumulated a shared set of synonymous mutations either before or after recombination, and subsequently diversified in different lineages resulting in the strains studied here.
Two of the three strains showed greater relative fitness in several phenotypic features than the initially isolated one or the parental Sabin 2 strain. The growth rate during the exponential phase of the replication cycle was clearly higher in the two most mutated PV2/PV1 recombinants. The exponential growth phase started more than 2 h earlier than in parental Sabin 2, especially in colonic and neuronal cells. As the maximum titres were reached by 12 h p.i., the 2 h advantage in a competition situation could be crucial. Furthermore, the effect of this advantage was proved by the competition assay, where the studied recombinant prevailed over its parental Sabin 2 in all studied cell lines. In support of the above findings, we also showed that PV3/ PV1 and PV3/PV2 recombinant strains had phenotypic differences when compared with the parental Sabin strains. Again, both of the studied recombinant strains showed greater relative fitness than their parental Sabin strains, as shown by growth rate analyses.
The stability of the PV2/PV1 recombinant strains was studied by using a temperature sensitivity assay. The results of the assay show that the two most mutated PV2/PV1 recombinants had lost their temperature sensitivity and behaved as wild-type strains. The basis for this was seen in the 59 NCR of the genome, where nt 481, considered responsible for attenuation and temperature sensitivity (Macadam et al., 1991; Ren et al., 1991) , had reverted back to wild-type. However, this change was seen in all PV2/PV1 recombinant strains and in PV2-31996, isolated 1 week after the first dose of OPV. This strain showed some reduction in the replication efficiency at elevated temperatures. Furthermore, both PV3 recombinants had the corresponding reversion at nt 472, considered to be responsible for temperature sensitivity and neurovirulence (Macadam et al., 1989; Minor et al., 1989; Westrop et al., 1989) . Besides the reversion of the attenuation-defining nucleotide, all studied strains also had other point mutations in the 59 NCR, possibly contributing to the increased fitness.
The competition assay showed that PV1 predominated over PV2 after five consecutive passages. Moreover, Sabin 1 replicated more efficiently than Sabins 2 and 3 in all cell lines, especially in the early stages of the replication cycle. This may be due to a more efficient attachment to cells or alternatively more efficient function of 3D polymerase. In the studied PV2/PV1 strains, the recombination site is at the 39 end of the non-structural part of the genome. Thus, the genomic stretch providing recombinant variability to the Sabin 2 genome is relatively short, though this sequence provides approximately 1200 nt of PV1 RNA dependent RNA polymerase and an amino acid change compared with Sabin 1. However, even the least mutated recombinant, PV2-31996, replicated faster than parental Sabin 2. The observed plaque sizes support this finding; the plaque sizes of all studied PV2/PV1 recombinants were larger than those of the parental Sabin strains (data not shown). Moreover, similar phenotypic results were achieved with the PV3/PV1 recombinant with the same amino acid change in the 3D gene. This emphasizes the significance of recombination. One hypothesis is that the PV1 3D polymerase is more efficient than that of PV2. Thus, it would be advantageous to PV2 or PV3 to gain a recombinant tail from PV1. Furthermore, the strains may have gained more replication power by accepting a recombinant tail with a possibly advantageous amino acid substitution. However, in the case of PV3/PV2, the growth advantage in the exponential phase of the replication cycle was evident as well. In this case, the PV2 tail had provided the PV3 strain with several possibly advantageous mutations.
In light of our results, it would seem plausible that the accumulation of point mutations is a key factor needed for a virus to gain the benefits of the observed phenotypic changes. PV2 recombinants with the wild-type threonine at aa 143 in VP1 had significant phenotypic differences from the third recombinant which had the attenuating isoleucine at the same position. The findings also emphasize the relevance of the mutation in the 3D polymerase coding region (aa 1998) for PV1, shared by all studied strains, as well as nt 481 in the 59 NCR for PV2 and nt 472 in the 59 NCR for PV3. Other secondary nucleotide or amino acid changes may be important for explaining the observations. In the 2C protein, recombinants PV2-32191 and PV2-32189+AP1 had several distinct mutations in addition to the shared nucleotide change in nt 4473 of the loop of CRE that could have an effect on replication efficiency. Interestingly, nt 4473 was the same as in wild-type PV2-Lansing and PV2-W2 as well as PV1 strains Sabin and Mahoney. Protein 2C has two functions in viral RNA synthesis: (i) as an ATPase and (ii) directing replication complexes to cell membranes forming replication complexes (Goodfellow et al., 2000) . It is possible that this change partly contributes to the faster replication. Further studies are needed to show the significance of distinct mutations or combinations of them.
The effects that pure recombination have on giving an advantage to a virus may not be excluded based on the results of this study. However, as mentioned above, it was not possible to judge this due to several point mutations in all strains. The parental Sabin 2 and Sabin 3 strains have a lower replication efficiency than PV2/PV1, PV3/PV1 or PV3/PV2 recombinants. This may be a capacity enriched by increasing mutations, but it could also reflect better qualities of the incorporated non-structural region. It has been suggested previously that recombination may be used as a means to gain advantageous point mutations (Agol, 2006) . We conclude that it would seem useful for a virus to use recombination as a means of gaining fitness, increasing the number of point mutations generated and selected in previous generations.
